Neutrophils often predominate the immune landscape in NSCLC microenvironments and can limit the efficacy of immune-checkpoint blockade treatment options such as anti-PD-L1 therapy (Rapoport et al., 2020). The gene discussed is CD274; the disease is non-small cell lung carcinoma.